A citation-based method for searching scientific literature

Don H Mahad, Bruce D Trapp, Hans Lassmann. Lancet Neurol 2015
Times Cited: 652







List of co-cited articles
796 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
Alan J Thompson, Brenda L Banwell, Frederik Barkhof, William M Carroll, Timothy Coetzee, Giancarlo Comi, Jorge Correale, Franz Fazekas, Massimo Filippi, Mark S Freedman,[...]. Lancet Neurol 2018
24

Defining the clinical course of multiple sclerosis: the 2013 revisions.
Fred D Lublin, Stephen C Reingold, Jeffrey A Cohen, Gary R Cutter, Per Soelberg Sørensen, Alan J Thompson, Jerry S Wolinsky, Laura J Balcer, Brenda Banwell, Frederik Barkhof,[...]. Neurology 2014
22

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Xavier Montalban, Stephen L Hauser, Ludwig Kappos, Douglas L Arnold, Amit Bar-Or, Giancarlo Comi, Jérôme de Seze, Gavin Giovannoni, Hans-Peter Hartung, Bernhard Hemmer,[...]. N Engl J Med 2017
892
19

Progressive multiple sclerosis: pathology and pathogenesis.
Hans Lassmann, Jack van Horssen, Don Mahad. Nat Rev Neurol 2012
583
18

Multiple Sclerosis.
Daniel S Reich, Claudia F Lucchinetti, Peter A Calabresi. N Engl J Med 2018
987
17


Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Ludwig Kappos, Amit Bar-Or, Bruce A C Cree, Robert J Fox, Gavin Giovannoni, Ralf Gold, Patrick Vermersch, Douglas L Arnold, Sophie Arnould, Tatiana Scherz,[...]. Lancet 2018
437
13

Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque.
Josa M Frischer, Stephen D Weigand, Yong Guo, Nilufer Kale, Joseph E Parisi, Istvan Pirko, Jay Mandrekar, Stephan Bramow, Imke Metz, Wolfgang Brück,[...]. Ann Neurol 2015
341
13

Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.
Roberta Magliozzi, Owain Howell, Abhilash Vora, Barbara Serafini, Richard Nicholas, Maria Puopolo, Richard Reynolds, Francesca Aloisi. Brain 2007
916
13

Iron and neurodegeneration in the multiple sclerosis brain.
Simon Hametner, Isabella Wimmer, Lukas Haider, Sabine Pfeifenbring, Wolfgang Brück, Hans Lassmann. Ann Neurol 2013
316
13

Progressive multiple sclerosis: from pathophysiology to therapeutic strategies.
Simon Faissner, Jason R Plemel, Ralf Gold, V Wee Yong. Nat Rev Drug Discov 2019
169
12

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.
Kathleen Hawker, Paul O'Connor, Mark S Freedman, Peter A Calabresi, Jack Antel, Jack Simon, Stephen Hauser, Emmanuelle Waubant, Timothy Vollmer, Hillel Panitch,[...]. Ann Neurol 2009
604
12

Cortical demyelination and diffuse white matter injury in multiple sclerosis.
Alexandra Kutzelnigg, Claudia F Lucchinetti, Christine Stadelmann, Wolfgang Brück, Helmut Rauschka, Markus Bergmann, Manfred Schmidbauer, Joseph E Parisi, Hans Lassmann. Brain 2005
12

The relation between inflammation and neurodegeneration in multiple sclerosis brains.
Josa M Frischer, Stephan Bramow, Assunta Dal-Bianco, Claudia F Lucchinetti, Helmut Rauschka, Manfred Schmidbauer, Henning Laursen, Per Soelberg Sorensen, Hans Lassmann. Brain 2009
921
11

Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging.
Assunta Dal-Bianco, Günther Grabner, Claudia Kronnerwetter, Michael Weber, Romana Höftberger, Thomas Berger, Eduard Auff, Fritz Leutmezer, Siegfried Trattnig, Hans Lassmann,[...]. Acta Neuropathol 2017
187
11

Immunopathology of multiple sclerosis.
Calliope A Dendrou, Lars Fugger, Manuel A Friese. Nat Rev Immunol 2015
11



Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Stephen L Hauser, Amit Bar-Or, Giancarlo Comi, Gavin Giovannoni, Hans-Peter Hartung, Bernhard Hemmer, Fred Lublin, Xavier Montalban, Kottil W Rammohan, Krzysztof Selmaj,[...]. N Engl J Med 2017
861
10


Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Fred Lublin, David H Miller, Mark S Freedman, Bruce A C Cree, Jerry S Wolinsky, Howard Weiner, Catherine Lubetzki, Hans-Peter Hartung, Xavier Montalban, Bernard M J Uitdehaag,[...]. Lancet 2016
271
10

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.
Robert J Fox, Christopher S Coffey, Robin Conwit, Merit E Cudkowicz, Trevis Gleason, Andrew Goodman, Eric C Klawiter, Kazuko Matsuda, Michelle McGovern, Robert T Naismith,[...]. N Engl J Med 2018
141
10

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Jerry S Wolinsky, Douglas L Arnold, Bruno Brochet, Hans-Peter Hartung, Xavier Montalban, Robert T Naismith, Marianna Manfrini, James Overell, Harold Koendgen, Annette Sauter,[...]. Lancet Neurol 2020
50
20

Multiple sclerosis.
Alan J Thompson, Sergio E Baranzini, Jeroen Geurts, Bernhard Hemmer, Olga Ciccarelli. Lancet 2018
797
10

Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI.
Assunta Dal-Bianco, Günther Grabner, Claudia Kronnerwetter, Michael Weber, Barbara Kornek, Gregor Kasprian, Thomas Berger, Fritz Leutmezer, Paulus Stefan Rommer, Siegfried Trattnig,[...]. Brain 2021
59
16

Progressive multiple sclerosis: from pathogenic mechanisms to treatment.
Jorge Correale, María I Gaitán, María C Ysrraelit, Marcela P Fiol. Brain 2017
266
10

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.
Chris H Polman, Stephen C Reingold, Brenda Banwell, Michel Clanet, Jeffrey A Cohen, Massimo Filippi, Kazuo Fujihara, Eva Havrdova, Michael Hutchinson, Ludwig Kappos,[...]. Ann Neurol 2011
9

Axonal transection in the lesions of multiple sclerosis.
B D Trapp, J Peterson, R M Ransohoff, R Rudick, S Mörk, L Bö. N Engl J Med 1998
9

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Raju Kapoor, Pei-Ran Ho, Nolan Campbell, Ih Chang, Aaron Deykin, Fiona Forrestal, Nisha Lucas, Bei Yu, Douglas L Arnold, Mark S Freedman,[...]. Lancet Neurol 2018
167
9

Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo.
Martina Absinta, Pascal Sati, Federica Masuzzo, Govind Nair, Varun Sethi, Hadar Kolb, Joan Ohayon, Tianxia Wu, Irene C M Cortese, Daniel S Reich. JAMA Neurol 2019
159
9

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
Xavier Montalban, Douglas L Arnold, Martin S Weber, Ivan Staikov, Karolina Piasecka-Stryczynska, Jonathan Willmer, Emily C Martin, Fernando Dangond, Sana Syed, Jerry S Wolinsky. N Engl J Med 2019
139
9

Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis.
Owain W Howell, Cheryl A Reeves, Richard Nicholas, Daniele Carassiti, Bishan Radotra, Steve M Gentleman, Barbara Serafini, Francesca Aloisi, Federico Roncaroli, Roberta Magliozzi,[...]. Brain 2011
510
9

A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis.
Roberta Magliozzi, Owain W Howell, Cheryl Reeves, Federico Roncaroli, Richard Nicholas, Barbara Serafini, Francesca Aloisi, Richard Reynolds. Ann Neurol 2010
453
9


An updated histological classification system for multiple sclerosis lesions.
Tanja Kuhlmann, Samuel Ludwin, Alexandre Prat, Jack Antel, Wolfgang Brück, Hans Lassmann. Acta Neuropathol 2017
273
9

Multiple sclerosis: an immune or neurodegenerative disorder?
Bruce D Trapp, Klaus-Armin Nave. Annu Rev Neurosci 2008
8

Multiple sclerosis.
Massimo Filippi, Amit Bar-Or, Fredrik Piehl, Paolo Preziosa, Alessandra Solari, Sandra Vukusic, Maria A Rocca. Nat Rev Dis Primers 2018
445
8

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.
Jeremy Chataway, Nadine Schuerer, Ali Alsanousi, Dennis Chan, David MacManus, Kelvin Hunter, Val Anderson, Charles R M Bangham, Shona Clegg, Casper Nielsen,[...]. Lancet 2014
269
8

Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis.
Sabina Luchetti, Nina L Fransen, Corbert G van Eden, Valeria Ramaglia, Matthew Mason, Inge Huitinga. Acta Neuropathol 2018
146
8

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.
Colm Elliott, Jerry S Wolinsky, Stephen L Hauser, Ludwig Kappos, Frederik Barkhof, Corrado Bernasconi, Wei Wei, Shibeshih Belachew, Douglas L Arnold. Mult Scler 2019
72
11

The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells.
Joana Machado-Santos, Etsuji Saji, Anna R Tröscher, Manuela Paunovic, Roland Liblau, Galina Gabriely, Christian G Bien, Jan Bauer, Hans Lassmann. Brain 2018
232
8

Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Stephen L Hauser, Amit Bar-Or, Jeffrey A Cohen, Giancarlo Comi, Jorge Correale, Patricia K Coyle, Anne H Cross, Jerome de Seze, David Leppert, Xavier Montalban,[...]. N Engl J Med 2020
169
8

Inflammatory cortical demyelination in early multiple sclerosis.
Claudia F Lucchinetti, Bogdan F G Popescu, Reem F Bunyan, Natalia M Moll, Shanu F Roemer, Hans Lassmann, Wolfgang Brück, Joseph E Parisi, Bernd W Scheithauer, Caterina Giannini,[...]. N Engl J Med 2011
705
8

Defining secondary progressive multiple sclerosis.
Johannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis, Tim Spelman, Eva Havrdova, Dana Horakova, Maria Trojano, Guillermo Izquierdo, Marc Girard, Pierre Duquette,[...]. Brain 2016
193
7

Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis.
Manuel A Friese, Benjamin Schattling, Lars Fugger. Nat Rev Neurol 2014
364
7

Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.
Ari J Green, Jeffrey M Gelfand, Bruce A Cree, Carolyn Bevan, W John Boscardin, Feng Mei, Justin Inman, Sam Arnow, Michael Devereux, Aya Abounasr,[...]. Lancet 2017
237
7

Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Jeremy Chataway, Floriana De Angelis, Peter Connick, Richard A Parker, Domenico Plantone, Anisha Doshi, Nevin John, Jonathan Stutters, David MacManus, Ferran Prados Carrasco,[...]. Lancet Neurol 2020
59
11

Multiple Sclerosis: Mechanisms and Immunotherapy.
Clare Baecher-Allan, Belinda J Kaskow, Howard L Weiner. Neuron 2018
388
7

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.
C Lucchinetti, W Brück, J Parisi, B Scheithauer, M Rodriguez, H Lassmann. Ann Neurol 2000
7

Oxidative damage in multiple sclerosis lesions.
Lukas Haider, Marie T Fischer, Josa M Frischer, Jan Bauer, Romana Höftberger, Gergö Botond, Harald Esterbauer, Christoph J Binder, Joseph L Witztum, Hans Lassmann. Brain 2011
455
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.